Key facts
- This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for Adicet Bio, Inc. (ACET).
- 4 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 09 Apr 2026, 17:38.
ORBIMED ADVISORS LLC - 07 Apr 2026 Form 4 Insider Report for Adicet Bio, Inc. (ACET)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- ACET
- Reported as of
- 07 Apr 2026
- Net transaction value
- -$674,847
- SEC form
- 4
- Accepted by SEC
- 09 Apr 2026, 17:38:36 UTC
- Prior SEC filing
- 04 Feb 2026
- Next SEC filing
- 16 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
ORBIMED ADVISORS LLC filed Form 4 for Adicet Bio, Inc. (ACET) on 09 Apr 2026.
Change
- Previous filing in this sequence was filed on 04 Feb 2026.
- Current net transaction value: -$674,847.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (8)
CIK 0001055951
Primary reporting owner
ORBIMED ADVISORS LLC
- Relationship
- 10%+ Owner
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
- Signature date
- 09 Apr 2026
CIK 0001615374
OrbiMed Capital GP V LLC
- Relationship
- 10%+ Owner
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Capital GP V LLC
- Signature date
- 09 Apr 2026
CIK 0001682115
OrbiMed Capital GP VI LLC
- Relationship
- 10%+ Owner
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Capital GP VI LLC
- Signature date
- 09 Apr 2026
CIK 0001808744
OrbiMed Genesis GP LLC
- Relationship
- 10%+ Owner
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Genesis GP LLC
- Signature date
- 09 Apr 2026
CIK 0001682093
OrbiMed Advisors Israel II Ltd
- Relationship
- 10%+ Owner
- Address
- 5 HAHOSHLIM STREET, BUILDING B, 1ST FLOOR, HERZLIYA, ISRAEL
- Signature
- /s/ Carl L. Gordon, Director of OrbiMed Israel GP Ltd.
- Signature date
- 09 Apr 2026
CIK 0001682090
OrbiMed Israel GP II, L.P.
- Relationship
- 10%+ Owner
- Address
- 5 HAHOSHLIM STREET, BUILDING B, 1ST FLOOR, HERZLIYA, ISRAEL
- Signature
- /s/ Carl L. Gordon, Director of OrbiMed Advisors Israel II Ltd.
- Signature date
- 09 Apr 2026
CIK 0001569590
OrbiMed Israel GP Ltd.
- Relationship
- 10%+ Owner
- Address
- 5 HAHOSHLIM STREET, BUILDING B, 1ST FLOOR, HERZLIYA, ISRAEL
- Signature
- /s/ Carl L. Gordon, Director of OrbiMed Israel GP II, L.P.
- Signature date
- 09 Apr 2026
CIK 0001569821
OrbiMed Israel BioFund GP Limited Partnership
- Relationship
- 10%+ Owner
- Address
- 5 HAHOSHLIM STREET, BUILDING B, 1ST FLOOR, HERZLIYA, ISRAEL
- Signature
- /s/ Carl L. Gordon, Director of OrbiMed Israel BioFund GP Limited Partnership
- Signature date
- 09 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACET
transaction
Common Stock
Sale
- Transaction value
- $191,453
- Shares
- -29,319
- Change %
- -46%
- Price
- $6.53
- Shares after
- 34,923
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $191,453
- Shares
- -29,319
- Change %
- -46%
- Price
- $6.53
- Shares after
- 34,923
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $191,453
- Shares
- -29,319
- Change %
- -46%
- Price
- $6.53
- Shares after
- 34,923
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $191,453
- Shares
- -29,319
- Change %
- -46%
- Price
- $6.53
- Shares after
- 34,923
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $191,453
- Shares
- -29,319
- Change %
- -46%
- Price
- $6.53
- Shares after
- 34,923
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $191,453
- Shares
- -29,319
- Change %
- -46%
- Price
- $6.53
- Shares after
- 34,923
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $191,453
- Shares
- -29,319
- Change %
- -46%
- Price
- $6.53
- Shares after
- 34,923
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $191,453
- Shares
- -29,319
- Change %
- -46%
- Price
- $6.53
- Shares after
- 34,923
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $15,312
- Shares
- -2,400
- Change %
- -6.9%
- Price
- $6.38
- Shares after
- 32,523
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $15,312
- Shares
- -2,400
- Change %
- -6.9%
- Price
- $6.38
- Shares after
- 32,523
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $15,312
- Shares
- -2,400
- Change %
- -6.9%
- Price
- $6.38
- Shares after
- 32,523
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $15,312
- Shares
- -2,400
- Change %
- -6.9%
- Price
- $6.38
- Shares after
- 32,523
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $15,312
- Shares
- -2,400
- Change %
- -6.9%
- Price
- $6.38
- Shares after
- 32,523
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $15,312
- Shares
- -2,400
- Change %
- -6.9%
- Price
- $6.38
- Shares after
- 32,523
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $15,312
- Shares
- -2,400
- Change %
- -6.9%
- Price
- $6.38
- Shares after
- 32,523
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $15,312
- Shares
- -2,400
- Change %
- -6.9%
- Price
- $6.38
- Shares after
- 32,523
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $204,570
- Shares
- -32,523
- Change %
- -100%
- Price
- $6.29
- Shares after
- 0
- Date
- 08 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $204,570
- Shares
- -32,523
- Change %
- -100%
- Price
- $6.29
- Shares after
- 0
- Date
- 08 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $204,570
- Shares
- -32,523
- Change %
- -100%
- Price
- $6.29
- Shares after
- 0
- Date
- 08 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $204,570
- Shares
- -32,523
- Change %
- -100%
- Price
- $6.29
- Shares after
- 0
- Date
- 08 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $204,570
- Shares
- -32,523
- Change %
- -100%
- Price
- $6.29
- Shares after
- 0
- Date
- 08 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $204,570
- Shares
- -32,523
- Change %
- -100%
- Price
- $6.29
- Shares after
- 0
- Date
- 08 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $204,570
- Shares
- -32,523
- Change %
- -100%
- Price
- $6.29
- Shares after
- 0
- Date
- 08 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $204,570
- Shares
- -32,523
- Change %
- -100%
- Price
- $6.29
- Shares after
- 0
- Date
- 08 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $263,512
- Shares
- -40,416
- Change %
- -100%
- Price
- $6.52
- Shares after
- 0
- Date
- 08 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F2, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $263,512
- Shares
- -40,416
- Change %
- -100%
- Price
- $6.52
- Shares after
- 0
- Date
- 08 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F2, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $263,512
- Shares
- -40,416
- Change %
- -100%
- Price
- $6.52
- Shares after
- 0
- Date
- 08 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F2, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $263,512
- Shares
- -40,416
- Change %
- -100%
- Price
- $6.52
- Shares after
- 0
- Date
- 08 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F2, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $263,512
- Shares
- -40,416
- Change %
- -100%
- Price
- $6.52
- Shares after
- 0
- Date
- 08 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F2, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $263,512
- Shares
- -40,416
- Change %
- -100%
- Price
- $6.52
- Shares after
- 0
- Date
- 08 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F2, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $263,512
- Shares
- -40,416
- Change %
- -100%
- Price
- $6.52
- Shares after
- 0
- Date
- 08 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F2, F6
ACET
transaction
Common Stock
Sale
- Transaction value
- $263,512
- Shares
- -40,416
- Change %
- -100%
- Price
- $6.52
- Shares after
- 0
- Date
- 08 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F2, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 78,499
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F3, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 78,499
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F3, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 78,499
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F3, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 78,499
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F3, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 78,499
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F3, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 78,499
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F3, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 78,499
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F3, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 78,499
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F3, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 564,147
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F4, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 564,147
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F4, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 564,147
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F4, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 564,147
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F4, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 564,147
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F4, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 564,147
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F4, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 564,147
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F4, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 564,147
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F4, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 280,640
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F5, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 280,640
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F5, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 280,640
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F5, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 280,640
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F5, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 280,640
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F5, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 280,640
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F5, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 280,640
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F5, F6
ACET
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 280,640
- Date
- 07 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F5, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
ORBIMED ADVISORS LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 6 footnotes
Footnote F1
These securities are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power over the shares of common stock held by OIP and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel GP exercises this investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP.
Footnote F2
These securities are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("OrbiMed Israel GP II") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited ("OrbiMed Israel II") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power over the shares of common stock held by OIP II and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel II exercises this investment and voting power through an investment committee comprised of Carl L. Gordon, David Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP II.
Footnote F3
These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by Genesis and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by Genesis.
Footnote F4
These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI V and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI V.
Footnote F5
These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VI and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VI.
Footnote F6
Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, Genesis GP, GP V, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.